On January 11, 2021 Tiziana Life Sciences plc (NASDAQ: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, reported that it is participating in Biotech Showcase 2021 and providing an on-demand company presentation (Press release, Tiziana Life Sciences, JAN 11, 2021, View Source [SID1234573807]). Registered attendees to Biotech Showcase can now access recorded company presentations prior to the actual event. 24×7 on-demand access allows attendees to view presentations at their convenience, avoiding conflicts with busy meeting schedules during the main event week.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Kunwar Shailubhai, CEO and CSO of Tiziana Life Sciences, commented, "I look forward to sharing our exciting story with conference attendees. With topline data from our COVID-19 trial expected this month, multiple Phase 2 trial launches expected in 2021, and the potential application of Foralumab in a wide range of autoimmune and inflammatory diseases longer-term, we are well positioned to achieve a series of important milestones that can provide a positive and lasting impact on our valuation in the months and quarters ahead."

Biotech Showcase, produced by Demy-Colton and EBD Group, is an investor conference focused on driving advances in therapeutic development by providing a sophisticated networking platform for executives and investors that fosters investment and partnership opportunities. The conference takes place each year during the course of one of the industry’s largest gatherings and busiest weeks.

"We are delighted that Tiziana Life Sciences will be presenting at Biotech Showcase this year," said Sara Demy, CEO of Demy-Colton. "Biotech Showcase is a prime occasion for life science entrepreneurs and investors to come together to discover the potential of innovative technologies that will drive the future of drug discovery."

On January 11, 2021 Navrogen, Inc., a biopharmaceutical company specialized in developing therapies for cancer and immune-related disorders, and the National Cancer Institute (NCI), part of the National Institutes of Health, reported that have established a research collaboration aimed at testing mesothelin-targeting therapies for the treatment of cancers where humoral immunity is suppressed (Press release, Navrogen, JAN 11, 2021, View Source [SID1234573806]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Mesothelin is a cell surface protein over-expressed on various malignancies, including lung cancer and mesothelioma. Certain therapeutic antibodies that use humoral immune function to kill cancer cells as well as antibody-drug conjugates (ADCs) targeting mesothelin are negatively affected by Humoral Immuno-Oncology (HIO) factors that are produced in the tumor microenvironment. To overcome this mechanism of HIO suppression, Navrogen has employed its proprietary HIO factor screening and block-removed immunoglobulin technology (BRITE) to engineer HIO refractory mesothelin-targeting agents.

The collaboration with the Thoracic and GI Malignancies Branch at NCI’s Center for Cancer Research, led by Raffit Hassan, M.D., is a joint effort to analyze ADCs for in vivo efficacy against human mesothelioma models developed by the Hassan laboratory. A major focus of the Hassan laboratory is developing mesothelin-targeted agents for treating cancer to include the development of mesothelioma patient-derived xenografts that mimic the molecular characteristics of patient tumors. Navrogen and NCI will combine their expertise and experimental resources to enable the comprehensive characterization of mesothelin targeting ADCs as agents for future human studies against mesothelin-expressing cancers including mesothelioma.

"We have engineered a HIO-refractory anti-mesothelin ADC (NAV-001) that will be tested in collaboration with NCI researchers by employing their patient-derived tumor models that are clinically relevant to mesothelioma and lung cancer," commented Dr. Luigi Grasso, Navrogen’s Chief Scientific Officer. "Results of these studies will aid in determining optimal dosing and tumor subtypes for Navrogen to pursue clinically".

On January 11, 2021 MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, reported that the Company’s management will participate in the following investor conferences in January (Press release, MacroGenics, JAN 11, 2021, View Source [SID1234573805]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright & Co. BioConnect 2021 Conference. A corporate overview provided by MacroGenics’ management will be available for on-demand viewing from January 11 – 14, 2021. In addition, MacroGenics’ President & Chief Executive Officer, Scott Koenig, M.D., Ph.D., will participate in a panel discussion on Precision Medicine hosted by Scott Gottlieb, M.D., Former Commissioner of the U.S. Food and Drug Administration. The panel will cover the importance of biomarkers and cytogenetic profiling in drug discovery, development and commercialization and will take place on Wednesday, January 13, 2021, at noon ET.
39th Annual J.P. Morgan Healthcare Conference. MacroGenics’ management will participate in one-on-one meetings and provide a corporate overview on January 14, 2021 at 10:00 AM ET.
Webcasts of the above presentations may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics’ website at View Source The Company will maintain archived replays of these webcasts on its website for 30 days after each conference.

On January 11, 2021 Cerus Corporation (Nasdaq: CERS) reported preliminary product revenue for the fourth quarter and full year 2020 and provided 2021 product revenue guidance (Press release, Cerus, JAN 11, 2021, View Source [SID1234573804]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cerus’ unaudited preliminary product revenue for the fourth quarter of 2020 totaled $28.2 million, an increase of 35% over the $20.9 million recognized during the same period in the prior year. Based on its fourth quarter unaudited preliminary product revenue, the Company expects full year 2020 product revenue of $91.9 million, exceeding the Company’s current 2020 product guidance range of $89 million to $91 million. The preliminary product revenue results have not been audited and are subject to change.

Preliminary fourth quarter product revenue would represent the highest quarterly product revenue ever reported by Cerus.

"Despite the challenges that our blood center customers, hospitals and we have faced with the COVID-19 pandemic, demand for INTERCEPT continues to grow impressively. While we anticipate that COVID-19 may still impact our access to blood centers and hospitals in the U.S. and western Europe in 2021, we nonetheless expect to see continued growth in INTERCEPT platelet kit demand, particularly in the U.S. as the new October 1 deadline for compliance with the FDA guidance on bacterial safety approaches," said William ‘Obi’ Greenman, Cerus’ president and chief executive officer.

"2021 will also mark our first sales of a biologic therapeutic product – Pathogen Reduced Cryoprecipitated Fibrinogen Complex. Our initial, limited launch will be a building phase ahead of a much broader, nationally focused rollout we expect in 2022. Based on our interactions and work to date, we are encouraged by the clinician reception to the new product and look forward to introducing the first manufactured products to hospitals for transfusion to patients this year," continued Greenman.

Despite ongoing pandemic-related customer access limitations, the Company expects full year 2021 product revenue will be in the range of $106 million to $110 million, representing growth of approximately 15% to 20% compared to preliminary unaudited 2020 full year results. This growth is expected to be driven by strong platelet kit demand in the U.S., as well as expected continued market adoption in targeted international markets.

Cerus will provide complete fourth quarter and full year 2020 financial results and host a call to discuss both 2020 results and 2021 expectations in late February.

On January 11, 2021 UroGen Pharma Presented the Corporate Presentation (Press release, UroGen Pharma, JAN 11, 2021, View Source [SID1234573803]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!